Literature DB >> 8736329

Ferrochelatase activities in patients with erythropoietic protoporphyria and their families.

G Goerz1, S Bunselmeyer, K Bolsen, N Y Schürer.   

Abstract

Ferrochelatase, estimated as zinc chelatase, was measured in the lymphocytes of 30 patients with erythropoietic protoporphyria (EPP), in 35 first- or second-degree relatives of patients with EPP, and in 50 healthy controls. In 30 EPP patients the zinc chelatase level (mean +/- standard deviation, SD) was 0.45 +/- 0.10 nmol of zinc protoporphyrin per hour per milligram of protein, in 14 EPP carriers the zinc chelatase level (mean +/- SD) was 0.42 +/- 0.09 and in 50 healthy controls the zinc chelatase level (mean +/- SD) was 0.84 +/- 0.27. All patients with EPP were also demonstrated to have an elevated protoporphyrin level in their red blood cells: the erythrocyte protoporphyrin levels were as follows EPP patients (mean +/- SD) 1300 +/- 758 nmol protoporphyrin/dl, EPP carriers (mean +/- SD) 60 +/- 24, and healthy controls (mean +/- SD) 50 +/- 25 (P < 0.001 for EPP patients compared to controls and EPP carriers). The families of 12 out of 15 EPP patients were examined with respect to the mode of inheritance of the disorder. Of 35 relatives, 14 were carriers of EPP, as characterized by reduced zinc chelatase activity in lymphocytes and by a normal protoporphyrin level in red blood cells. None of the 14 EPP carriers had presented with clinical symptoms of EPP. The mod of inheritance was autosomal dominant in seven of the 12 examined families, and autosomal recessive in two. In two families only one parent could be investigated, but we nevertheless concluded that the inheritance was autosomal dominant. Inheritance in one EPP family could not be elucidated as both parents showed normal zinc chelatase levels and did not demonstrate abnormal erythrocyte protoporphyrin levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8736329

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

Review 1.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

Review 2.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Gut       Date:  2007-03-14       Impact factor: 23.059

Review 3.  Erythropoietic protoporphyria.

Authors:  T M Cox
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

4.  Production and characterization of erythropoietic protoporphyric heterodimeric ferrochelatases.

Authors:  Wided Najahi-Missaoui; Harry A Dailey
Journal:  Blood       Date:  2005-04-14       Impact factor: 22.113

5.  ATP-dependent mitochondrial porphyrin importer ABCB6 protects against phenylhydrazine toxicity.

Authors:  Dagny L Ulrich; John Lynch; Yao Wang; Yu Fukuda; Deepa Nachagari; Guoqing Du; Daxi Sun; Yiping Fan; Lyudmila Tsurkan; Philip M Potter; Jerold E Rehg; John D Schuetz
Journal:  J Biol Chem       Date:  2012-01-31       Impact factor: 5.157

Review 6.  Porphyria Diagnostics-Part 1: A Brief Overview of the Porphyrias.

Authors:  Vaithamanithi-Mudumbai Sadagopa Ramanujam; Karl Elmo Anderson
Journal:  Curr Protoc Hum Genet       Date:  2015-07-01

7.  Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria.

Authors:  Laurent Gouya; Caroline Martin-Schmitt; Anne-Marie Robreau; Frederic Austerlitz; Vasco Da Silva; Patrick Brun; Sylvie Simonin; Said Lyoumi; Bernard Grandchamp; Carole Beaumont; Herve Puy; Jean-Charles Deybach
Journal:  Am J Hum Genet       Date:  2005-11-15       Impact factor: 11.025

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.